Axsome Therapeutics, Inc. Forecasted to Earn Q2 2022 Earnings of ($1.05) Per Share (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) – Research analysts at William Blair reduced their Q2 2022 earnings per share estimates for Axsome Therapeutics in a report released on Monday, May 2nd. William Blair analyst M. Minter now anticipates that the company will post earnings of ($1.05) per share for the quarter, down from their prior forecast of ($0.93). William Blair also issued estimates for Axsome Therapeutics’ Q3 2022 earnings at ($1.16) EPS, Q4 2022 earnings at ($1.14) EPS, FY2022 earnings at ($3.35) EPS, Q1 2023 earnings at ($0.56) EPS, Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.25) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($1.26) EPS and FY2024 earnings at $5.82 EPS.

A number of other research firms have also recently issued reports on AXSM. StockNews.com started coverage on Axsome Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research cut shares of Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 target price on the stock. in a report on Friday, March 4th. SVB Leerink cut their price objective on shares of Axsome Therapeutics from $65.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Mizuho cut their target price on shares of Axsome Therapeutics from $51.00 to $49.00 in a research report on Tuesday. Finally, Jefferies Financial Group increased their price objective on shares of Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Buy” and an average target price of $80.58.

AXSM opened at $38.50 on Thursday. The company has a fifty day moving average price of $35.40 and a 200-day moving average price of $34.46. Axsome Therapeutics has a one year low of $19.38 and a one year high of $74.10. The firm has a market capitalization of $1.48 billion, a P/E ratio of -10.35 and a beta of 2.47. The company has a debt-to-equity ratio of 3.14, a current ratio of 3.75 and a quick ratio of 3.75.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.00) by ($0.03). During the same quarter in the prior year, the firm earned ($0.78) earnings per share.

Institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its stake in shares of Axsome Therapeutics by 122.8% in the second quarter. Morgan Stanley now owns 317,446 shares of the company’s stock valued at $21,414,000 after purchasing an additional 174,980 shares during the period. Commonwealth Equity Services LLC purchased a new stake in Axsome Therapeutics in the third quarter valued at approximately $491,000. Cambridge Investment Research Advisors Inc. increased its position in Axsome Therapeutics by 51.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 11,440 shares of the company’s stock worth $377,000 after purchasing an additional 3,905 shares in the last quarter. Deutsche Bank AG lifted its position in Axsome Therapeutics by 73.7% during the 3rd quarter. Deutsche Bank AG now owns 80,227 shares of the company’s stock worth $2,645,000 after acquiring an additional 34,029 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its position in Axsome Therapeutics by 42.3% in the 3rd quarter. Advisor Group Holdings Inc. now owns 5,901 shares of the company’s stock valued at $195,000 after buying an additional 1,754 shares during the last quarter. 48.46% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile (Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Further Reading

Earnings History and Estimates for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.